THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...

Researchers have found a way to trap telomerase, the enzyme cancer cells rely on for endless division, in a stalled and ...

Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. MAIA Biotechnology is developing a Telomerase-Mediated ...

CHICAGO, February 27, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for ...

THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...

THIO combined with Libtayo shows improved progression-free survival of 5.6 months versus 2.5 months with standard treatments in advanced non-small cell lung cancer. The THIO-101 trial indicates a ...

(RTTNews) - MAIA Biotechnology, Inc. (MAIA), a clinical-stage biopharmaceutical company, on Tuesday announced a clinical supply agreement with BeiGene to evaluate the efficacy of its lead drug ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could improve ...

First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding ...

Maia Biotechnology (NYSE:MAIA) stock rose ~10% after the company reported preliminary survival data in from Part A safety lead-in of an ongoing phase 2 trial of THIO in patients with advanced ...